Expression of vascular endothelial growth factor, hypoxia inducible factor 1alpha, and carbonic anhydrase IX in human tumours. - Wikidata - awgldk - TriplyDB

Expression of vascular endothelial growth factor, hypoxia inducible factor 1alpha, and carbonic anhydrase IX in human tumours.

Expression of vascular endothelial growth factor, hypoxia inducible factor 1alpha, and carbonic anhydrase IX in human tumours.

http://www.wikidata.org/entity/Q35587630

about

Altered patterns of transcription of the septin gene, SEPT9, in ovarian tumorigenesis Dual Regulation of Cell Death and Cell Survival upon Induction of Cellular Stress by Isopimara-7,15-Dien-19-Oic Acid in Cervical Cancer, HeLa Cells In vitro Clinicopathological and prognostic significance of hypoxia-inducible factor-1 alpha in lung cancer: a systematic review with meta-analysis.Vasohibin inhibits angiogenic sprouting in vitro and supports vascular maturation processes in vivo.Bevacizumab and breast cancer: current therapeutic progress and future perspectives A new peptide ligand for targeting human carbonic anhydrase IX, identified through the phage display technology.Membrane carbonic anhydrase IX expression and relapse risk in resected stage I-II non-small-cell lung cancer Early growth response-1 induces and enhances vascular endothelial growth factor-A expression in lung cancer cells Transcriptome sequencing of the blind subterranean mole rat, Spalax galili: utility and potential for the discovery of novel evolutionary patterns Primary tumor vascularity, HIF-1α and VEGF expression in vulvar squamous cell carcinomas: their relationships with clinicopathological characteristics and prognostic impact.TREEGL: reverse engineering tree-evolving gene networks underlying developing biological lineages.Hypoxia-inducible factor in thyroid carcinoma Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer.VEGF-B promotes cancer metastasis through a VEGF-A-independent mechanism and serves as a marker of poor prognosis for cancer patients Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis.ZD6474--a novel inhibitor of VEGFR and EGFR tyrosine kinase activity Role and mechanism of hypoxia-inducible factor-1 in cell growth and apoptosis of breast cancer cell line MDA-MB-231 Hypoxia Induces Epithelial-Mesenchymal Transition in Follicular Thyroid Cancer: Involvement of Regulation of Twist by Hypoxia Inducible Factor-1α.PlGF-induced VEGFR1-dependent vascular remodeling determines opposing antitumor effects and drug resistance to Dll4-Notch inhibitors.Mechanisms of glioma-associated neovascularization.How will lung cancer be treated in the future?Prognostic Relevance of the Expression of CA IX, GLUT-1, and VEGF in Ovarian Epithelial Cancers.Serum 8-OHdG and HIF-1α levels: do they affect the development of malignancy in patients with hypoactive thyroid nodules?HIF-1alpha and HIF-2alpha have divergent roles in colon cancer.Discontinuation of anti-VEGF cancer therapy promotes metastasis through a liver revascularization mechanism.Bevacizumab in the therapy for refractory metastatic colorectal cancer.Expression of delta-like ligand 4 (Dll4) and markers of hypoxia in colon cancer.Impact of tumor cell VEGF expression on the in vivo efficacy of vandetanib (ZACTIMA; ZD6474).Dose KRAS Mutation Status Affect on the Effect of VEGF Therapy in Metastatic Colon Cancer Patients?Induction of erythropoiesis by hypoxia-inducible factor prolyl hydroxylase inhibitors without promotion of tumor initiation, progression, or metastasis in a VEGF-sensitive model of spontaneous breast cancer.Bevacizumab in combination with IFN-α in metastatic renal cell carcinoma: the AVOREN trial.Guidelines and considerations for conducting experiments using tissue microarrays.VEGF-targeted cancer therapeutics-paradoxical effects in endocrine organs.Future options of anti-angiogenic cancer therapy.Expression of hypoxia-inducible factor 1 alpha in thyroid carcinomas Investigation of tumor hypoxia using a two-enzyme system for in vitro generation of oxygen deficiency.Inhibition of AGS Cancer Cell Proliferation following siRNA-Mediated Downregulation of VEGFR2.Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer Vascular phenotypes in primary non-small cell lung carcinomas and matched brain metastases.Expression of HIF-1 alpha in human tumours.

P2860

Q28272119-39027A55-16CE-4708-9C98-56E306048DF8 Q28390946-B024561C-9A00-446B-BF0C-CD9A963745F3 Q30249160-2A7461F2-AC70-4F24-825D-149419C4F9C1 Q33493619-451B96A3-4A83-4CF4-BD60-DE26B1537F76 Q33640753-FCB1F41F-D11E-4B94-BDA7-C4C9F57F6E25 Q33786760-F8724C46-2D4E-472A-BCFF-ED44D70F4B15 Q33856008-8BE9210B-0B07-49A1-A597-8D824980E35D Q33947163-813C6A4D-99D0-45E6-9AD0-C575C42E5016 Q33998775-2EFCDF54-8D60-4015-A5DF-77C690BC8847 Q35027303-26087A9B-D14B-4A1A-94A5-D07AC601625C Q35051851-7BB70329-C667-4C4D-8E48-F1377AE5CD23 Q35099457-A0F343CB-7096-43EC-9614-4DD9C1476185 Q35588327-15A286FD-E607-4BC7-9D95-173EE4FAF16E Q35698934-9DD7C6AC-A0D4-45A4-954A-7B54866545A9 Q36112303-33EC445D-C89C-4B7E-917C-5471B0C627B2 Q36146888-ED5798EE-E901-4556-8DFB-49471C598872 Q36216542-AF5E8D70-C39A-4683-8B15-B1326F56EB8A Q36240123-B3C22FE5-44EB-452E-9208-F9C8012B649B Q36268182-5A222067-90AA-4BC1-A713-D53A495CE194 Q36295477-BBFA21F3-7178-4B1F-B351-49B66E1D1294 Q36429550-E8436C5B-E852-45F8-8FB3-21CE7CC5C877 Q36518752-B3C4D465-C796-430E-B6D4-72FEB91D5A09 Q36936711-8197F85A-3EE6-4BBD-88B8-195268F3E45F Q37192848-46403E71-BE1D-4B21-AFBA-FAF8487D1622 Q37260920-40DDA7AA-0D81-4507-AEF6-BBB07A658FD5 Q37307590-4E9E2A6C-9394-4615-9489-A043094D76B5 Q37424106-AEB3A665-34D4-449A-9EF0-0D5649E40A75 Q37451272-74A74708-43FC-4391-9751-4F116AB3134B Q37570370-E5B4688C-7138-42C4-A9BB-D1833F345613 Q37705646-CA028A69-A9FD-4A5B-97AA-FC0B085E959C Q38058530-0D3F2C9C-7F86-4404-878F-F492DDA7BD58 Q38106730-779C3481-76BF-41BD-9072-12C8B5FEDA4F Q38232368-AE6402A9-F4B3-40F4-B2C3-E5F52D32E7E5 Q38438425-ABAD3891-07A2-4C19-848F-E41C439388AF Q39285064-AC1D46DA-6382-4FE7-A155-611A1B90DCBD Q39561817-47F33BDC-9CF0-49C3-8DA9-E4FBCBC31305 Q41015064-2D7906F8-5C80-47E9-A24E-83B427C3FE6D Q42000250-73DFD1BB-24C7-4F04-965C-502094E15C17 Q42750671-E1383D2B-2A7B-448E-9727-7823AFD500CC Q43010095-69A1D416-7B70-43D7-90C5-9F882BEF49A8

P2860

Expression of vascular endothelial growth factor, hypoxia inducible factor 1alpha, and carbonic anhydrase IX in human tumours.

http://www.wikidata.org/entity/Q35587630

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

Expression of vascular endothe ...... anhydrase IX in human tumours.

@ast

Expression of vascular endothe ...... anhydrase IX in human tumours.

@en

type

label

Expression of vascular endothe ...... anhydrase IX in human tumours.

@ast

Expression of vascular endothe ...... anhydrase IX in human tumours.

@en

prefLabel

Expression of vascular endothe ...... anhydrase IX in human tumours.

@ast

Expression of vascular endothe ...... anhydrase IX in human tumours.

@en

P1433

Q35587630-73A3EB75-795F-4E50-911D-D739F6F20B1D

P1476

Q35587630-F2D18BBE-3C1A-4DC1-A36A-238B772D91E7

P2093

Q35587630-0E4E31BE-D2F1-4FA5-8D36-C99B0048213A

Q35587630-256E75DE-ECFA-4B93-9759-D1927C33336E

Q35587630-409D014C-EF86-4488-9C43-2098E6F065AC

Q35587630-50302A1C-100E-4F61-A2A3-BA3942268C4C

Q35587630-79D2DF7C-DC0E-4EC7-AAA7-6C4089B05B9C

Q35587630-82364212-FE24-4CED-90EE-07763ACBA225

Q35587630-B1AA9F78-1452-4505-9498-2BCBCBAA9B50

Q35587630-CF63CBAE-614B-4D7A-82B8-BF6F00E7A94D

P2860

Q35587630-0906B583-4552-4DE4-BACF-26E21AD769AC

Q35587630-09E514D0-1355-4108-A1AE-CDCA622DF783

Q35587630-0C8B8279-C77F-4651-8321-48862BA08344

Q35587630-1DE6C612-9A02-45BE-8070-C371560BFBBE

Q35587630-2422346D-B347-4E4B-ABD7-51B784E10352

Q35587630-2C2A2D5E-FC57-4266-9110-A0CD906D68E0

Q35587630-338097AE-B4C7-417D-915F-1260DA9C0E83

Q35587630-35702007-5B11-4243-BA7B-30C23B3C06DE

Q35587630-3D2AD50B-A5C3-496A-9BC1-55CCFDF1FA43

Q35587630-457071ED-5F06-4689-B4F5-18645E183503

P304

Q35587630-192AABC1-E996-41A4-8289-2EA0B6CE2A88

P31

Q35587630-DD667BC9-3B06-4A07-9E4F-963D48F46C9C

P356

Q35587630-A53EAED6-905A-47BD-B315-61AE14ECCA9C

P407

Q35587630-13DAFC8E-AAD5-4281-AD57-6C7A5548AF76

P433

Q35587630-437501DA-9263-414C-AFCE-EE1E89230A4D

P478

Q35587630-78B18629-462C-4E7E-93A4-210C29FD834C

P577

Q35587630-4FCBBB4E-6CFF-4919-8BAB-1D76201AA84D

P5875

Q35587630-42DE0744-C041-44D0-A516-BBC8C4D62FA9

P698

Q35587630-9035B36A-E0E8-4C0E-A0B1-75FFEF3E4769

P921

Q35587630-588DFBBF-4B5B-45BB-A949-D13CE8D1283E

Q35587630-6D74EFAC-78AD-4DD0-B469-C6A03ACBF6E6

P932

Q35587630-7A616BF4-9FA9-4252-A093-A504ACFD9C44

P356

JCP.2003.012963

P1433

Journal of Clinical Pathology

P1476

Expression of vascular endothe ...... anhydrase IX in human tumours.

@en

P2093

A M Hanby

http://www.w3.org/2001/XMLSchema#string

A M Jubb

http://www.w3.org/2001/XMLSchema#string

F V Peale

http://www.w3.org/2001/XMLSchema#string

G D Frantz

http://www.w3.org/2001/XMLSchema#string

H W Koeppen

http://www.w3.org/2001/XMLSchema#string

K J Hillan

http://www.w3.org/2001/XMLSchema#string

T D Wu

http://www.w3.org/2001/XMLSchema#string

T Q Pham

http://www.w3.org/2001/XMLSchema#string

P2860

HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing

C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation

Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension

Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation

Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases

The Expression and Distribution of the Hypoxia-Inducible Factors HIF-1α and HIF-2α in Normal Human Tissues, Cancers, and Tumor-Associated Macrophages

HIF-1 and tumor progression: pathophysiology and therapeutics

Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha

Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis

Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1

P304

504-512

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/JCP.2003.012963

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

57

http://www.w3.org/2001/XMLSchema#string

P577

2004-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

277530366

http://www.w3.org/2001/XMLSchema#string

P698

15113858

http://www.w3.org/2001/XMLSchema#string

P921

P932

1770303

http://www.w3.org/2001/XMLSchema#string